CTKB
Cytek Biosciences, Inc.4.7000
+0.0600+1.29%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A reaffirms turnaround, adds color
Q&A largely reaffirmed prepared remarks on the 2025 turnaround, pinning Q4 acceleration on academic and government budget normalization plus NIH catch-up, not pharma rebound. Management plans continued commercial investments targeting weak segments and reagents, with pricing staying market-driven amid competitive costs. They see APAC outpacing a lagging Europe, U.S. in between, and flow cytometry rebounding to high single digits globally. Pent-up demand was hard to parse. Guidance assumes strong service/reagent growth, flat-to-modest instruments, plus contingency cushion. Q&A stayed light on surprises. Investors will watch instrument durability amid uncertainties.
Key Stats
Market Cap
600.96MP/E (TTM)
-Basic EPS (TTM)
-0.11Dividend Yield
0%Recent Filings
8-K
Q4 revenue hits record $62.1M
Cytek Biosciences posted Q4 revenue of $62.1M, up 8% year-over-year—its record quarterly high—while full-year 2025 revenue edged 1% higher to $201.5M, with recurring revenue surging 21% to 34% of total. Adjusted EBITDA fell to $5.0M amid rising op-ex. Guides 2026 revenue to $205M-$212M. Cash steady at $261.5M.
10-K
FY2025 results
Cytek Biosciences posted FY2025 revenue of $201.5 million, up 1% y/y from $200.5 million, with service revenue accelerating 21% to $57.3 million on a growing installed base while product sales dipped 6% to $144.2 million amid softer instrument demand. Q4 margins held steady despite headwinds, but full-year gross margin compressed to 52% from 55% on higher tariffs and overhead from manufacturing shifts. Yet cash remains robust at $261.5 million after $15 million in buybacks. No annual guidance disclosed in the 10-K. Supply chain disruptions from sole-source vendors threaten quarterly momentum.
8-K
Q4 revenue hits $62M
Cytek Biosciences announced preliminary unaudited 2025 revenue of ~$201M, with Q4 at ~$62M—up 8% from Q4 2024 and 19% from Q3 2025. Growth accelerated via strong services, reagents, Asia Pacific instruments, plus US/EMEA instrument rebound. Trends gaining steam. Full results and 2026 guidance due late February; figures preliminary, subject to audit.
8-K
Q3 revenue up 2%, recurring +19%
Cytek Biosciences posted Q3 revenue of $52.3 million, up 2% year-over-year, with recurring revenue surging 19% and installed base hitting 3,456 instruments after adding 161 units. EMEA softness offset gains elsewhere, while GAAP gross margin slipped to 53% and ops loss widened to $9.2 million amid litigation costs. Cash sits steady at $261.7 million. Reaffirms 2025 revenue guide of $196M-$205M.
10-Q
Q3 FY2025 results
Cytek posted Q3 revenue of $52.3M, up 2% y/y but flat q/q (derived), with service revenue jumping 19% y/y to $14.2M from a bigger installed base while product sales dipped 4% y/y on EMEA softness offset by APAC gains. Gross margin slipped to 53% from 56% y/y on higher service labor costs and product overhead. Operating loss widened to $9.2M from $4.2M y/y as G&A surged 47% on patent litigation; net loss hit $5.5M or $(0.04) per diluted share (127.5M shares, anti-dilution flagged). Cash dipped to $93.3M with $168.5M marketable securities; long-term debt under $1M; FCF not disclosed in the 10-Q. Cash burn continues. Patent suits loom large.
A
Agilent Technologies, Inc.
139.19-1.41
AVTR
Avantor, Inc.
11.20-0.08
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
CERS
Cerus Corporation
2.16+0.15
CTSO
Cytosorbents Corporation
0.64+0.01
LAB
Standard BioTools Inc.
1.49-0.02
MXCT
MaxCyte, Inc.
1.47-0.02
PACB
Pacific Biosciences of Californ
2.02-0.10
SSMXF
Sysmex Corp.
9.33+0.00